WC
FBRX

Weil Company’s Forte Biosciences FBRX Stock Holding History

Weil Company’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Hold
24,765
– – 0.09% 88
2026
Q1 		$641K Buy
+24,765
New +$713K 0.14% 76

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Weil Company's FBRX Position: Q2 2026 in Review

Weil Company held its Forte Biosciences (FBRX) position steady in Q2 2026 at 24,765 shares worth $526K. The position accounts for 0.09% of the portfolio, ranked #88.

Weil Company first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $641K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Weil Company held 24,765 shares of Forte Biosciences worth $526K as of Q2 2026.
  • Weil Company left its Forte Biosciences share count unchanged in Q2 2026.
  • Forte Biosciences made up 0.09% of Weil Company's portfolio in Q2 2026, its #88 holding.
  • Weil Company first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Weil Company's Forte Biosciences position peaked at $641K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Weil Company's 13F filing for Q2 2026, filed 5 Aug 2026.